Updates are available Correction dated 2021-02-16
Click to view Correction: https://doi.org/10.1186/s13063-021-05109-8
-
Authors
,
-
Funding
Funding for this research was provided by:
UPMC Learning While Doing Program
Breast Cancer Research Foundation in collaboration with the Translational Breast Cancer Research Consortium
Global Coalition for Adaptive Research
Amgen
Eisai
ACTIV-4
- License Information
-
More Information
Article History
Received: 8 August 2020
Accepted: 22 December 2020
First Online: 28 January 2021
Change Date: 19 February 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13063-021-05109-8
Ethics approval and consent to participate
: The University of Pittsburgh IRB and Western IRB approved the trial described in this manuscript. Informed consent will be obtained from all study participants.
: Not applicable.
: MB is Chief Executive Officer of the Global Coalition for Adaptive Research, a 501(C) [] nonprofit organization. SB reports being a part owner of Berry Consultants, LLC (a company that designs and implements platform and adaptive clinical trials for pharmaceutical companies, medical device companies, National Institutes of Health (NIH) cooperative groups, international consortia and non- profit organizations), and providing consulting for platform trials. DCA is the UPMC chief healthcare innovation officer.
